The search continues for effective chemotherapeutic agents in the treatment of disseminated carcinoma. Some patients with disseminated carcinoma of the breast have responded to treatment with alkylating agents (Wright, Golomb, and Gumport, 1958; Olson, 1958; Moore, 1958; Gurling, 1959) . The following is a report of the clinical effects of therapy with a hitherto untried alkylating agent, mannitol busulphan (mannitol myleran; C.B.251 1).
Clmincal Material
Patients with extensive carcinoma of the breast or prostate are referred here for consideration for hypophysectomy, which is undertaken only when disease is disseminated or when extensive inoperable local disease is present. In all, 15 patients have received mannitol busulphan; 14 of these had undergone previous hypophysectomy. Mannitol busulphan was given when evidence was obtained of renewed progression of disease after hypophysectomy or when it became clear that hypophysectomy had failed to influence the continued progression of disease. Of the 15 patients treated, 11 with extensive breast carcinoma received enough of the drug to produce bone-marrow depression. Four patients-three with breast carcinoma and one with disseminated carcinoma of the prostate-received small doses of mannitol busulphan preterminally and all died within a month of starting therapy. These four cases are shown in Table I , but are not further discussed.
Among the 11 patients who received adequate therapy widely disseminated disease was present in 10 (Table II) . One patient who had an extensive recurrence in the scar area 18 months after radical mastectomy was treated with mannitol busulphan prior to pituitary ablation. She had failed to respond to earlier hormone therapy. This patient was hypertensive and had had a myocardial infarct after radical mastectomy.
Reponse to previous hypophysectomy had occurred in five patients and five had failed to obtain even temporary remission after hypophysectomy, but four of the latter had obtained earlier remissions of disseminated disease after other hormonal therapy. Those (Timmis and Brown, 1960) (Fig. 1) Damage to the bone-marrow occurred in all patients. In those given 6-9 g. weekly in divided doses, depression of the white blood count occurred about three weeks after the start of therapy, followed rapidly by recovery of the count on withdrawal of the drug or reduction in dose. This is illustrated in Fig. 2 . The granulocytes were depressed chiefly, and in one patient (Case 4) graduated doses resulted in fatal agranulocytosis. This patient, however, had received treatment with another alkylating agent, chlorambucil, eight months previously.
Cases 6-11 who received large doses initially, over a short period of time, developed agranulocytosis. This developed two to three weeks after the start of therapy and lasted for 9 to 15 days. The haemoglobin concentration and platelet count also fell. The lymphocyte counts were relatively less depressed (Fig. 3) . Baron, 1961) occurred in 5 of the 11 patients treated.
Two of cases 1-5 who were given graduated weekly doses responded to therapy. In one (case 5) a decrease in bone pain occurred and the re-epithelization of extensive chest-wall ulcers started. However, the improvement lasted for six weeks only. The second patient (case 2) has extensive osteolytic lesions. This patient is still receiving mannitol busulphan after 17 months of treatment. Bony lesions have not recalcified while she has been on therapy, but she has had complete relief from severe bone pain. No new osseous lesions have appeared while she has been receiving treatment, but bone pain has recurred two to three weeks after the temporary cessation of therapy on three occasions.
Three of six patients (cases 6-11) who received large initial doses of mannitol busulphan showed objective response to therapy. One of three patients in whom no objective evidence of response has yet occurred has been treated only recently, and so far has shown marked subjective improvement, with total relief of bone pain. In three patients who improved after large initial doses, subjective evidence of improvement was apparent during the stage of agranulocytosis when this produced no symptoms, or was noted after recovery from agranulocytosis. In Case 7 bone pain was decreased, osseous lesions have remained static, and pulmonary lesions have decreased in size radiologically. In one patient (Case 6) who had ascites, peritoneal masses, and supraclavicular glands a single intraperitoneal dose of mannitol busulphan was given.
On Small recurrent skin nodules decreased in size in a third patient treated with large doses of mannitol busulphan. One patient obtained relief of severe pain due to involvement of the brachial plexus, but no objective evidence of improvement was found. She died of bronchitis four weeks after treatment started, when her leucocytes, which had fallen to 450/c.mm., had recovered. Discussion Improvement and objective temporary remission of disseminated breast carcinoma has been obtained by the use of mannitol busulphan. Two of five patients given smaller doses obtained some benefit, and three, possibly four, of six patients who were given larger doses obtained objective improvement. It is probable that the degree of benefit depends on the amount of drug administered, and unless enough is given to damage the bone-marrow the effect on the growth is likely to be negligible.
Several reports of the treatment of disseminated carcinoma of the breast with alkylating agents have appeared. In most series between one-third and onefifth of the patients treated have responded (Moore, 1958; Gurling, 1959) . It has been suggested that patients who respond well to other forms of treatment may have a better chance of benefiting from chemotherapy (Gurling, 1959) . In all but one of the patients treated in this series response to mannitol busulphan has been similar to that which followed previous hypophysectomy. Hypophysectomy, however, was undertaken in some as a final hormonal resort, and response to chemotherapy is not similar in all cases to the response to hormonal therapy prior to hypophysectomy. Many of the difficulties of treating malignant disease are inherent in the unique biological properties of malignant cells. These cells, though independent, share many properties with host cells; thus an effective anticancer agent is more than likely to produce an effect on the cells of the host similar to that which it exhibits on the cells of the tumour, though perhaps differing in degree.
Anti-cancer agents in use at the present time are either cytotoxic or hormonal, the former including both the alkylating agents and the antimetabolites. This communication is concerned only with the alkylating agents. To use these effectively some method is required to protect the host cells from their effect, particularly on such tissues as bone-marrow and alimentary tract.
From this basic requirement has grown the concept of isolated regional perfusion, which is an attempt to isolate a tumour in its own vascular bed from the remainder of the body's circulatory system. By this method the isolated tumour-bearing vascular territory is perfused with blood into which can be introduced the appropriate cytotoxic agent in such a manner as to maintain an effective concentration for a given period of time.
Continuous regional intra-arterial infusion -first described by Klopp-is a simpler procedure with a different set of indications. This method is not considered here.
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